Overview

A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy

Status:
RECRUITING

Trial end date:
2026-03-12

Target enrollment:

Participant gender:

Summary

Thyroid-associated ophthalmopathy (TAO) is a serious, progressive, vision-threatening autoimmune disease that can be categorized into mild, moderate, and severe stages based on severity. The activity of TAO is commonly evaluated using the Clinical Activity Score (CAS). Tocilizumab serves as a second-line treatment option for patients with moderate to severe active TAO. Additionally, it is common for TAO patients to experience anxiety, which may exacerbate their condition and negatively impact prognosis. Therefore, we have designed this randomized controlled study to evaluate the impact of Flupentixol Melitracen (Lepan) on the treatment outcomes of participants receiving Tocilizumab (Actemra).

Phase:

PHASE4

Details

Lead Sponsor:

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Treatments:

Control Groups
flupentixol, melitracen drug combination
tocilizumab